Plandai Biotechnology Inc (OTCMKTS:PLPL) has announced the expansion of the partnership with USN. According to reports, USN has decided to market Plandai’s premium green tea ingredient Phytofare in two new markets — New Zealand and Australia. Both the firms had entered into an agreement previously, under which USN was to use Phytofare in all the green tea products developed or sold in Europe and South Africa.
The senior management teams of both the companies are delighted to take their partnership to the next level. According to Callum Baylis-Duffield, VP-Sales & Marketing, Plandai, USN has done a tremendous job when it comes to increasing Phytofare’s reach in the given timeline. Phytofare is equipped with active ingredients that are beneficial to blood and remain intact in the bloodstream longer than normal supplements. They bring positive results to consumers in the long run.
As the awareness level of people has increased, they want supplements that are healthy for their bodies and can have a positive impact on their overall lifestyle. The way USN has taken Phytofare from South Africa and Europe to New Zealand and Australia market is incredible. Based on the market response, both of them will decide how they should mold their association in the future.
Meanwhile Metabolix, Inc. (NASDAQ:MBLX) has decided to form a dedicated team of experts having a keen focus on the improvement of crop yields. The company has named this initiative Yield10 Bioscience. As per the reports, the prime objective of Yield10 Bioscience is to develop innovative solutions and then commercialize them on a wide level.
Herborium Group, Inc. (OTCMKTS:HBRM) has decided to launch a host of next generation websites that can focus on spreading information about its flagship product AcnEase. It is capable of providing natural treatments for acne and rosacea. As per the reports, this launch is a part of a global promotional campaign that Herborium started in June 2015.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: